NCT05699603View on ClinicalTrials.gov

Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 2, 2024

Primary Completion Date

February 1, 2027

Study Completion Date

February 1, 2029

Conditions

Actinic Keratosis

Interventions

PROCEDURE

Biopsy

Undergo skin biopsy

DRUG

Calcipotriene

Applied topically

DRUG

Fluorouracil

Applied topically

Trial Locations (4)

63110

Washington University School of Medicine, St Louis

85719

University of Arizona Cancer Center - Prevention Research Clinic, Tucson

97239

Oregon Health and Science University, Portland

02114

Massachusetts General Hospital Cancer Center, Boston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Arizona

OTHER

NCT05699603 - Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients | Biotech Hunter | Biotech Hunter